rs180922748
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PM5BP4_StrongBP6BS2
The NM_001365536.1(SCN9A):āc.3832C>Gā(p.Leu1278Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0021 in 1,576,608 control chromosomes in the GnomAD database, including 9 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L1278I) has been classified as Pathogenic.
Frequency
Consequence
NM_001365536.1 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN9A | NM_001365536.1 | c.3832C>G | p.Leu1278Val | missense_variant | 21/27 | ENST00000642356.2 | NP_001352465.1 | |
SCN1A-AS1 | NR_110260.1 | n.612-14763G>C | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN9A | ENST00000642356.2 | c.3832C>G | p.Leu1278Val | missense_variant | 21/27 | NM_001365536.1 | ENSP00000495601 | P1 | ||
SCN1A-AS1 | ENST00000651574.1 | n.1290-14763G>C | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes AF: 0.00171 AC: 260AN: 151970Hom.: 1 Cov.: 31
GnomAD3 exomes AF: 0.00122 AC: 261AN: 214484Hom.: 0 AF XY: 0.00125 AC XY: 146AN XY: 117104
GnomAD4 exome AF: 0.00214 AC: 3052AN: 1424522Hom.: 8 Cov.: 29 AF XY: 0.00206 AC XY: 1456AN XY: 707200
GnomAD4 genome AF: 0.00171 AC: 260AN: 152086Hom.: 1 Cov.: 31 AF XY: 0.00172 AC XY: 128AN XY: 74354
ClinVar
Submissions by phenotype
not provided Uncertain:4Benign:3
Uncertain significance, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2024 | SCN9A: BS1 - |
Likely benign, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Jul 25, 2017 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Apr 21, 2021 | This variant is associated with the following publications: (PMID: 28440294, 23895530, 24776970, 24848745, 19763161, 25250524, 26284228, 29176367) - |
Uncertain significance, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Feb 28, 2022 | The SCN9A c.3799C>G; p.Leu1267Val variant (rs180922748) is reported in the literature in two patients with Dravet syndrome (Mulley 2013, Singh 2009). However, both individuals also carried a clearly pathogenic variant in a different gene associated with Dravet or similar seizure disorder. This variant was also reported in a case with diabetic peripheral neuropathy; however, the patient carried an additional variant in SCN11A (Blesneac 2018). This variant is reported in ClinVar (Variation ID: 195592) and is found in the non-Finnish European population with an allele frequency of 0.22% (261/117658 alleles) in the Genome Aggregation Database. The leucine at codon 1267 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.766). However, given the lack of clinical and functional data, the significance of the p.Leu1267Val variant is uncertain at this time. References: Blesneac I et al. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy. Pain. 2018 Mar;159(3):469-480. PMID: 29176367. Mulley et al. Role of the sodium channel SCN9A in genetic epilepsy with febrile seizures plus and Dravet syndrome. Epilepsia. 2013; 54(9): e122-6. PMID: 23895530. Singh et al. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet. 2009; 5(9): e1000649. PMID: 19763161. - |
not specified Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 24, 2015 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 31, 2023 | Variant summary: SCN9A c.3799C>G (p.Leu1267Val) results in a conservative amino acid change located in the Ion transport domain (IPR005821) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0012 in 214484 control chromosomes. This frequency does not allow conclusions about variant significance. Although appearing in the literature, to our knowledge, no penetrant association of c.3799C>G in individuals affected with SCN9A-related disorders such as Primary Erythermalgia/Hereditary Sensory Neuropathy type IID/Congenital insensitivity to pain and no conclusive experimental evidence demonstrating its impact on protein function have been reported. At-least one co-occurrence with another known variant in the GABRG2 gene in an individual reportedly affected with Dravet syndrome has been ascertained, providing supporting evidence for a benign role (Mulley_SCN9A_Epilepsia_2013). Ten clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 with a majority consensus as likely benign (n=7). Based on the evidence outlined above, the variant was classified as likely benign. - |
Childhood epilepsy with centrotemporal spikes Pathogenic:1
Pathogenic, no assertion criteria provided | case-control | Bioinformatics Core, Luxembourg Center for Systems Biomedicine | Jan 01, 2017 | CAADphred>15 - |
Inherited Erythromelalgia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Primary erythromelalgia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 14, 2022 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Channelopathy-associated congenital insensitivity to pain, autosomal recessive Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Generalized epilepsy with febrile seizures plus, type 7;C2752089:Neuropathy, hereditary sensory and autonomic, type 2A Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Paroxysmal extreme pain disorder Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at